跳到主要內容

臺灣博碩士論文加值系統

(44.222.189.51) 您好!臺灣時間:2024/05/26 20:21
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:李俐慧
研究生(外文):Li-Hui, Lee
論文名稱:新穎性秋水仙素衍生物AD1對食道癌之作用影響
論文名稱(外文):The effect of a novel colchicine derivative AD1 on human esophageal cancer
指導教授:劉俊仁劉俊仁引用關係
指導教授(外文):Jun-Jen Liu
學位類別:碩士
校院名稱:臺北醫學大學
系所名稱:醫學檢驗暨生物技術學系
學門:醫藥衛生學門
學類:醫學技術及檢驗學類
論文種類:學術論文
論文出版年:2012
畢業學年度:100
語文別:中文
論文頁數:117
中文關鍵詞:食道癌、微小管、秋水仙素、新穎性秋水仙素衍生物AD1、有絲分裂風暴、輻射
外文關鍵詞:Esophageal cancerAD1ColchicineMitotic catastropheChromosomeRadiation
相關次數:
  • 被引用被引用:0
  • 點閱點閱:224
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:1
目錄
摘要 i
Abstract ii
縮寫表 iii

第一章、研究背景 1
1.1食道癌 1
1.2食道癌的治療 2
1.3細胞週期與藥物發展 3
1.4 微管 (Microtubule)的作用與藥物的應用 6
1.5 新穎性秋水仙素衍生物AD1初步結果 10
第二章、研究特定目標 12
第三章、材料與方法 14
3.1實驗材料 14
3.2實驗方法 20
第四章、實驗結果 27
4.1生長抑制作用 27
4.2細胞型態 (Morphology)之變化 29
4.3細胞週期 (Cell cycle)變化 30
4.4西方墨點法 (Western Blot)之結果 31
4.5動物實驗 33
第五章、討論 34
5.1 新穎性秋水仙素衍生物AD1造成CE81T/VGH、SKGT4及BE3細胞株之生長抑制 34
5.2 AD1與有絲分裂風暴 (Mitotic catastrophe) 35
5.3 AD1造成CE81T/VGH、SKGT4及BE3細胞株中心體異常 43
5.4 AD1造成CE81T/VGH、SKGT4及BE3細胞在有絲分裂風暴後進行細胞凋亡 45
5.5 AD1與輻射增敏劑 45
第六章、結論與展望 48
第七章、參考文獻 49
第八章、圖表 58
圖一、秋水仙素、秋水仙素衍生物thiocolchicine與新穎性秋水仙素衍生物AD1結構圖、化學式與分子量 58
圖二、AD1對CE81T/VGH食道癌細胞生長之作用 59
圖三、AD1對SKGT4食道癌細胞生長之作用 60
圖四、AD1對BE3食道癌細胞生長之作用 61
圖五、Paclitaxel對CE81T/VGH食道癌細胞株生長之作用 62
圖六、Paclitaxel對SKGT4食道癌細胞株生長之作用 63
圖七、Paclitaxel對BE3食道癌細胞株生長之作用 64
圖八、AD1對CE81T/VGH食道癌細胞生長之作用圖 65
圖九、AD1對SKGT4食道癌細胞生長之作用圖 66
圖十、AD1對BE3食道癌細胞生長之作用圖 67
圖十一、AD1作用下,食道癌細胞株CE81T/VGH細胞型態變化 68
圖十二、AD1作用下,食道癌細胞株SKGT4細胞型態變化 69
圖十三、AD1作用下,食道癌細胞株BE3細胞型態變化 70
圖十四、食道癌細胞株CE81T/VGH細胞型態變化 71
圖十五、食道癌細胞株SKGT4細胞型態變化 72
圖十六、食道癌細胞株BE3細胞型態變化 73
圖十七、食道癌細胞株CE81T/VGH螢光染色細胞型態變化 76
圖十八、食道癌細胞株SKGT4螢光染色細胞型態變化 79
圖十九、食道癌細胞株BE3螢光染色細胞型態變化 82
圖二十、AD1對食道癌細胞株CE81T/VGH細胞週期之作用 83
圖二十一、AD1對食道癌細胞株SKGT4細胞週期之作用 84
圖二十二、AD1對食道癌細胞株BE3細胞週期之作用 85
圖二十三、AD1對細胞週期調控相關因子的影響 86
圖二十四、AD1對紡錘體檢查點相關因子的影響 88
圖二十五、AD1對DNA damage相關性因子的影響 90
圖二十六、ATM抑制劑caffeine造成DNA damage相關性蛋白質ATM活性表現 92
圖二十七、異種皮下移植人類食道癌動物模式 94
表一、AD1對食道癌細胞株CE81T/VGH之細胞週期之作用 95
表二、AD1對食道癌細胞株SKGT4之細胞週期之作用 96
表三、AD1對食道癌細胞株BE3之細胞週期之作用 97
附圖一、食道的構造圖 98
附圖二、食道癌的TNM分期圖示 99
附圖三、食道癌的TNM系統分類 100
附圖四、食道癌 (腺癌與鱗狀上皮細胞癌)TNM系統分期 101
附圖五、新穎性秋水仙素衍生物AD1與其他微管抑制劑生物毒性比較 102
附圖六、新穎性秋水仙素衍生物AD1對於各種類型肝癌細胞株的抑制作用 103
附圖七、新穎性秋水仙素衍生物AD1對於Hep J5細胞株細胞抑制型態的表現 104



1. 99 年死因簡報. 行政院衛生署 2010.
2. Tae Jung Kim MHYk, Kyung Won Lee, Moon Soo Kim: Multimodality Assessment of esophageal cancer-preoperative staging and monitoring of response to therapy. RadioGraphics 2009, 29:19.
3. Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, Fremgen AM.:Esophageal cancer. J Am Coll SURG 2000, 190:11.
4. Melhado RE, Alderson D, Tucker O.: The Changing Face of Esophageal Cancer. Cancers 2010, 2:1379-1404.
5. Varghese J, Graham Warren, Mary Kay Washington, Christopher Willett and R. Sasson,Walter J. Scott, Stephen Shibata, Vivian E. M. Strong, Thomas K. Mulcahy, Mark B.
Orringer, Raymond U. Osarogiagbon, James A. Posey, Aaron Keswani, Lawrence R. Kleinberg, W. Michael Korn, A. Craig Lockhart, Mary F., Glasgow JAH, Wayne L. Hofstetter,
David H. Ilson, Rajesh N. Prajnan Das, Crystal S. Denlinger, Charles S. Fuchs, Hans Gerdes, Robert E. Jaffer A. Ajani, James S. Barthel, David J. Bentrem, Thomas A. D''Amico, Cameron D. Wright: Esophageal and Esophagogastric Junction Cancers. Journal of the National Comprehensive Cancer Network 2011, 9:59.
6. 葉坤輝: 食道癌之化學與放射療法. 當代醫學 1998, 25:3.
7. Mariette C, Piessen, G., & Triboulet, J. P. : Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007, 8:9.
8. Bhamidipati CM, Stukenborg GJ, Thomas CJ, Lau CL, Kozower BD, Jones DR.: Pathologic Lymph Node Ratio Is a Predictor of Survival in Esophageal Cancer. Ann Thorac Surg
2012.
9. Ilson DH.: Esophageal Cancer Chemotherapy: Recent Advances. Gastrointest Cancer Res 2008, 2:8.
10. Rice TW, Blackstone EH, Rusch VW.: 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol 2010, 17:1721-1724.
11. Grunberger B, Raderer, M., Schmidinger, M., & Hejna, M.: Palliative chemotherapy for recurrent and metastatic esophageal cancer. Anticancer Res 2007, 27:10.
12. Kelsen DP, Ginsberg, R., Pajak, T. F., Sheahan, D. G., Gunderson, L., Mortimer, J., Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA.: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998, 339:6.
13. Law S, Fok, M., Chow, S., Chu, K.-M., & Wong, J.: Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: A prospective
randomized trial. J Thorac Cardiovasc Surg 1997, 114:8.
14. Schlag PM.: Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. Arch Surg 1992, 127:5.
15. Nygaard K, Hagen, S., Hansen, H. S., Hatlevoll, R., Hultborn, R., Jakobsen, A., Mäntyla M, Modig H, Munck-Wikland E, Rosengren B.: Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: A randomized, multicenter study of pre-operative
radiotherapy and chemotherapy. The second scandinavian trial in esophageal cancer. World J Surg 1992, 16:6.
16. Roth JA, Pass, H. I., Flanagan, M. M., Graeber, G. M., Rosenberg, J. C., & Steinberg, S.:Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy
with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988, 96:7.
17. Maipang T, Vasinanukorn, P., Petpichetchian, C., Chamroonkul, S, Geater, A,Chansawwaang, S, Kuapanich R, Panjapiyakul C, Watanaarepornchai S, Punperk S.:
Induction chemotherapy in the treatment of patients with carcinoma of the esophagus.J Surg Oncol 1994, 56:7.
18. Kok TC.: Chemotherapy in oesophageal cancer. Cancer Treat Rev 1997, 23:21.
19. Alberts B JA, Lewis J, Raff M, Roberts K, Walter P.: Molecular Biology of the Cell. Ch 17.Garland Science: New York 4th ed 2003.
20. Daniel PTK, U.; Schuppan, J. : Apoptolidin: induction of apoptosis by a natural product.Angew Chem Int Ed 2006, 45:22.
21. Igney FH., Krammer PH.: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002, 2:12.
22. Hanahan D., Weinberg RA.: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
23. Okada H., Mak TW.: Pathways of apoptotic and non-apoptotic death in tumour cells.Nat Rev Cancer 2004, 4:592-603.
24. Vitale I, Galluzzi L, Castedo M, Kroemer G: Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011, 12:385-392.
25. Molz L., Booher R., Young P., Beach D.: cdc2 and the Regulation of Mitosis: Six Interacting mcs Genes. Genetics 1989, 122:773-782.
26. Ayscough K., Hayles J., MacNeill SA., Nurse P.: Cold-sensitive mutants of p34cdc2 that suppress a mitotic catastrophe phenotype in fission yeast. Mol Gen Genet 1992,
232:344-350.
27. Russell P., Nurse P.: Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog. Cell 1987, 49:559-567.
28. Ayscough K., Hayles, J., MacNeill, S. A., Nurse, P. : Cold-sensitive mutants of p34cdc2 that suppress a mitotic catastrophe phenotype in fission yeast. Mol Gen Genet 1992,
3:7.
29. Kroemer G., El-Deiry WS., Golstein P., Peter ME., Vaux D., Vandenabeele P., Zhivotovsky B., Blagosklonny MV., Malorni W., Knight RA., Kumar S., Lipton SA., Malorni W., Nuñez G.,Peter ME., Tschopp J., Yuan J., Piacentini M., Zhivotovsky B., Melino G.: Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ 2005, 12 Suppl 2:1463-1467.
30. Castedo M., Perfettini JL., Roumier T., Andreau K., Medema R., Kroemer G.: Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004, 23:2825-2837.
31. José Portugal SMaMB: Mechanisms of Drug-Induced Mitotic Catastrophe in Cancer Cells. Current Pharmaceutical Design 2010, 16:10.
32. Dodson H., Wheatley SP., Morrison CG.: Involvement of centrosome amplification in radiation-induced mitotic catastrophe. Cell Cycle 2007, 6:364-370.
33. Blagosklonny MV.: Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 2007, 6:70-74.
34. Ianzini F., Mackey MA.: Spontaneous premature chromosome condensation and mitotic catastrophe following irradiation of HeLa S3 cells. Int J Radiat Biol 1997,
72:409-421.
35. Roninson IB., Broude EV., Chang BD.: If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 2001, 4:303-313.
36. Rieder CL., Maiato H.: Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004, 7:637-651.
37. Huang X., Tran T., Zhang L., Hatcher R., Zhang P.: DNA damage-induced mitotic catastrophe is mediated by the Chk1-dependent mitotic exit DNA damage checkpoint. Proc Natl Acad Sci U S A 2005, 102:1065-1070.
38. Vogel C., Hager C., Bastians H.: Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res 2007, 67:339-345.
39. Nitta M., Kobayashi O., Honda S., Hirota T., Kuninaka S., Marumoto T., Ushio Y., Saya H.:Spindle checkpoint function is required for mitotic catastrophe induced by
DNA-damaging agents. Oncogene 2004, 23:6548-6558.
40. Sato N., Mizumoto K., Nakamura M., Ueno H., Minamishima YA., Farber JL., Tanaka M.: A possible role for centrosome overduplication in radiation-induced cell death.Oncogene 2000, 19:5281-5290.
41. Loffler H., Lukas J., Bartek J., Kramer A.: Structure meets function--centrosomes,genome maintenance and the DNA damage response. Exp Cell Res 2006,312:2633-2640.
42. Vakifahmetoglu H., Olsson M., Tamm C., Heidari N., Orrenius S., Zhivotovsky B.: DNA damage induces two distinct modes of cell death in ovarian carcinomas. Cell Death Differ 2008, 15:555-566.
43. Schvartzman JM., Sotillo R., Benezra R.: Mitotic chromosomal instability and cancer:mouse modelling of the human disease. Nat Rev Cancer 2010, 10:102-115.
44. Manchado E., Guillamot M., Malumbres M.: Killing cells by targeting mitosis. Cell Death Differ 2012, 19:369-377.
45. Dumontet C., Jordan MA.: Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010, 9:790-803.
46. Howard J, Hyman AA.: Growth, fluctuation and switching at microtubule plus ends. Nat Rev Mol Cell Biol 2009, 10:569-574.
47. Akhmanova A, Steinmetz MO.: Tracking the ends: a dynamic protein network controls the fate of microtubule tips. Nat Rev Mol Cell Biol 2008, 9:309-322.
48. Coluccia A., Sabbadin D., Brancale A.: Molecular modelling studies on Arylthioindoles as potent inhibitors of tubulin polymerization. European Journal of Medicinal Chemistry 2011, 46:3519-3525. Diaz JFA, J. M.: Assembly of purified GDP-tubulin into microtubules induced by taxol
and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993,32:9.
50. Horwitz SB.: How to make taxol from scratch. Nature 1994, 367:2.
51. Manfredi JJP, J.; Horwitz, S. B.: Taxol binds to cell microtubules. J Cell Biol 1982, 94:9.
52. Jordan MA.: Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med ChemAnti-Canc Agents 2002, 2:17.
53. Pryor DEOB, A.; Bilcer, G.; Díaz, J. F.; Wang, Y.; Kabaki, M.; Jung, M. K.; Andreu, J. M.;Ghosh, A. K.; Giannakakou, P.; Hamel, E. : The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 2002, 41:7.
54. Na GCT, S. N.: Thermodynamic linkage between tubulin self-association and the binding of vinblastine. Biochemistry 1980, 19:8.
55. Plosker GLR, F. D.: A review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 2003, 63:41.
56. Jordan MAT, D.; Wilson, L.: Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 1991, 51:11.
57. Hamel E.: Natural products which interact with tubulin in the Vinca domain:maytansine, rhizoxin, phomopsin A, Dolastatins 10 and 15 and halichondrin B.Pharmacol Ther 1992, 55:21.
58. Skoufias DW, L.: Mechanism of inhibition of microtubule polymerization by colchicine:inhibitory potencies of unliganded colchicine and tubulin-colchicine complexes.
Biochemistry 1992:9.
59. Nam NH.: Combretastatin A-4 Analogues as Antimitotic Antitumor Agents. Cur Med Chem 2003, 10:26.
60. Yoshimatsu KY, A.; Yoshino, H.; Koyanagi, N; Kitoh, K.: Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the
colchicine site of tubulin. Cancer Res 1997, 57:16.
61. Levy EB-CaN: Colchieine; 1998 Update. Semin Arthritis Rheum 1998, 28:12.
62. Chen XM, Liu J, Wang T, Shang J.: Colchicine-induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicol In Vitro 2012.
63. Cocco G, Chu DC, Pandolfi S.: Colchicine in clinical medicine. A guide for internists. Eur J Intern Med 2010, 21:6.
64. V.J. Poirier AEH, K.E. Burgess, B. Phillips, M.M. Turek, L.J. Forrest, L. Beaver, and D.M. Vail:Efficacy and Toxicity of Paclitaxel (Taxol) for the Treatment of Canine Malignant Tumors.J Vet Intern Med 2004, 18:4.
65. Ilson DH KD.: Management of esophageal cancer. Oncology (Williston Park) 1996:12.
66. Rigas JR, Dragnev KH, Bubis JA.: Docetaxel in the Treatment of Esophageal Cancer.Semin Oncol 2005, 32:39-51.
67. Ajani JA ID, Daugherty K, Kelsen DP.: Paclitaxel in the treatment of carcinoma of the esophagus. Semin Oncol 1995, 22:6.
68. Ajani JA ID, Daugherty K, Pazdur R, Lynch PM, Kelsen DP.: Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer
Inst 1994, 86:6.
69. Mario Airoldi GC, Carlo Giordano, Fulvia Pedani, Cesare Bumma aPG: Docetaxel and Vinorelbine. Medical Oncology 2003, 20:6.
70. K. Gelmon F.: The taxoids: paclitaxel and docetaxel. The Lancet 1994, 344.
71. Eric K. Rowinsky MD, and Ross C. Donehower, M.D.: PACLITAXEL (TAXOL). N Engl J Med 1995, 332.
72. Noguchi E MY.: Chemotherapy-induced peripheral neuropathy. Gan To Kagaku Ryoho 2011, 38:4.
73. Ayako Mizota KS, Chihiro Kondo, Motoo Nomura, Tomoya Yokota, Daisuke Takahari,Takashi Ura, Kei Muro: A Retrospective Comparison of Docetaxel and Paclitaxel for
Patients with Advanced or Recurrent Esophageal Cancer Who Previously Received Platinum-Based Chemotherapy. Oncology 2011, 81:6.
74. Spencer CM, Faulds D.: Paclitaxel: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in the Treatment of Cancer.Drugs, 48:794-847.
75. Milas L MM, Mason KA.: Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 1999:15.
76. Susan Bane H.: Interactions of colchicine with tubulin. Pharmacology & Therapeutics 1991, 51:377-401.
77. Boye O BA.: Tropolonic Colchicum alkaloids and allo congeners. The Alkaloids 1992, 41.
78. Guan J., Zhu XK., Tachibana Y., Bastow KF., Brossi A., Hamel E., Lee KH.: Antitumor agents.Part 186: Synthesis and biological evaluation of demethylcolchiceinamide analogues as cytotoxic DNA topoisomerase II inhibitors. Bioorg Med Chem 1998, 6:2127-2131.
79. Qian Shi KC., Arnold Brossi., Pascal Verdier-Pinard., Ernest Hamel., Andrew T. McPhail, Kuo-Hsiung Lee: Antitumor Agents. Part 184.Syntheses and antitubulin activity of
compounds derived from reaction of thiocolchicone with amines: Lactams, alcohols,and ester analogs of allothiocolchicinoids. Helvetica Chimica Acta 1998, 81.
80. Brecht R., Seitz G., Guenard D., Thoret S.: Novel allocolchicinoids with an eight membered B-ring: design, synthesis and inhibition of tubulin assembly. Bioorg Med
Chem 2000, 8:557-562.
81. Pan XD., Fang WS.: Recent progress in structure-activity relationship studies on the anticancer drug colchicine and its analogues. Yao Xue Xue Bao 2002, 37:821-827.
82. Webb A., Cunningham D., Scarffe JH., Harper P., Norman A., Joffe JK., Hughes M., Mansi J., Findlay M., Hill A., Oates J., Nicolson M., Hickish T., O''Brien M., Iveson T., Watson M., Underhill C., Wardley A., Meehan M.: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997, 15:261-267.
83. Peter C. Enzinger MD, and Robert J. Mayer, M.D.: Esophageal Cancer. The new england journal of medicine 2003, 349 12.
84. Val Gebski BB., B Mark Smithers, Kerwyn Foo, John Zalcberg, John Simes: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma:a meta-analysis. The Lancet Oncology 2007, 8:9.
85. Herskovic A., Russell W., Liptay M., Fidler MJ., Al-Sarraf M.: Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol 2012, 23:1095-1103.
86. Roninson IB BE., Chang BD.: If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 2001, 4:11.
87. José Portugal MB., and Sylvia Mansilla: Cell death pathways in response to antitumor therapy. Tumori 2009, 95:13.
88. Rosenthal ET., Hunt T., Ruderman JV.: Selective translation of mRNA controls the pattern of protein synthesis during early development of the surf clam, Spisula
solidissima. Cell 1980, 20:487-494.
89. Hartwell LH., Weinert TA.: Checkpoints: controls that ensure the order of cell cycle events. Science 1989, 246:629-634.
90. Paulovich AG., Toczyski DP., Hartwell LH.: When checkpoints fail. Cell 1997, 88:315-321.
91. Kops GJ., Weaver BA., Cleveland DW.: On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005, 5:773-785.
92. Hwang A., Muschel RJ.: Radiation and the G2 phase of the cell cycle. Radiat Res 1998, 150:S52-59.
93. Spacey SD., Gatti RA., Bebb G.: The molecular basis and clinical management of ataxia telangiectasia. Can J Neurol Sci 2000, 27:184-191.
94. Matsuoka S., Huang M., Elledge SJ.: Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998, 282:1893-1897.
95. Musacchio A., Hardwick KG.: The spindle checkpoint: structural insights into dynamic signalling. Nat Rev Mol Cell Biol 2002, 3:731-741.
96. Stewart ZA., Westfall MD., Pietenpol JA.: Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci 2003, 24:139-145.
97. A.Nigg E.: MITOTIC KINASES AS REGULATORS OF CELL DIVISION AND ITS CHECKPOINTS. NATURE REVIEWS 2001, 2:12.
98. Rapley J., Baxter JE., Blot J., Wattam SL., Casenghi M., Meraldi P., Nigg EA., Fry AM.:Coordinate regulation of the mother centriole component nlp by nek2 and plk1
protein kinases. Mol Cell Biol 2005, 25:1309-1324.
99. De Luca M LP., Guarguaglini G.: A Functional Interplay Between Aurora-A, Plk1 and TPX2 at Spindle Poles. Cell Cycle 2006, 5:8.
100. Goto H., Kiyono T., Tomono Y., Kawajiri A., Urano T., Furukawa K., Nigg EA., Inagaki M.:Complex formation of Plk1 and INCENP required for metaphase-anaphase transition.
Nat Cell Biol 2006, 8:180-187.
101. Ahonen LJ., Kallio MJ., Daum JR., Bolton M., Manke IA., Yaffe MB., Stukenberg PT.,Gorbsky GJ.: Polo-like kinase 1 creates the tension-sensing 3F3/2 phosphoepitope and modulates the association of spindle-checkpoint proteins at kinetochores. Curr Biol
2005, 15:1078-1089.
102. Nishino M., Kurasawa Y., Evans R., Lin S-H., Brinkley BR., Yu-Lee L-y: NudC Is Required for Plk1 Targeting to the Kinetochore and Chromosome Congression. Current Biology 2006,16:1414-1421.
103. Neef R., Preisinger C., Sutcliffe J., Kopajtich R., Nigg EA., Mayer TU., Barr FA:Phosphorylation of mitotic kinesin-like protein 2 by polo-like kinase 1 is required for
cytokinesis. J Cell Biol 2003, 162:863-875.
104. Liu J., Lewellyn AL., Chen LG., Maller JL.: The polo box is required for multiple functions of Plx1 in mitosis. J Biol Chem 2004, 279:21367-21373.
105. Lens SM., Voest EE., Medema RH.: Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010, 10:825-841.
106. Mita AC., Mita MM., Nawrocki ST., Giles FJ.: Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics. Clinical Cancer Research 2008,14:5000-5005.
107. Rosa J.: Survivin Modulates Microtubule Dynamics and Nucleation throughout the Cell Cycle. Mol Biol Cell 2005, 17:1483-1493.
108. van der Waal MS., Hengeveld RC., van der Horst A., Lens SM.: Cell division control by the Chromosomal Passenger Complex. Exp Cell Res 2012.
109. Mita AC., Mita MM., Nawrocki ST., Giles FJ.: Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008, 14:5000-5005.
110. Saito T., Hama S., Izumi H., Yamasaki F., Kajiwara Y., Matsuura S., Morishima K., Hidaka T.,Shrestha P., Sugiyama K., Kurisu K.: Centrosome amplification induced by survivin
suppression enhances both chromosome instability and radiosensitivity in glioma cells.Br J Cancer 2008, 98:345-355.
111. Qing Chang Z-RL, Da-Yu Wang, Manoj Kumar, Yi-Bei Chen, Ren-Yi Qin: Survivin expression induced by doxorubicin in cholangiocarcinoma. World J Gastroenterol 2004,
10:4.
112. Fukasawa K.: Oncogenes and tumour suppressors take on centrosomes. Nat Rev Cancer 2007, 7:911-924.
113. Fukasawa K.: Introduction. Centrosome. Oncogene 2002, 21:6140-6145.
114. Srsen V., Merdes A.: The centrosome and cell proliferation. Cell Div 2006, 1:26.
115. Nigg EA.: Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer 2002, 2:815-825.
116. Wang Y., Ji P., Liu J., Broaddus RR., Xue F., Zhang W.: Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer 2009, 8:8.
117. Tarapore P., Horn HF., Tokuyama Y., Fukasawa K.: Direct regulation of the centrosome duplication cycle by the p53-p21Waf1/Cip1 pathway. Oncogene 2001, 20:3173-3184.
118. Fukasawa K., Choi T., Kuriyama R., Rulong S., Vande Woude GF.: Abnormal centrosome amplification in the absence of p53. Science 1996, 271:1744-1747.
119. Carroll PE., Okuda M., Horn HF., Biddinger P., Stambrook PJ., Gleich LL., Li YQ., Tarapore P.,Fukasawa K.: Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 1999, 18:1935-1944.
120. Dodson H., Bourke E., Jeffers LJ., Vagnarelli P., Sonoda E., Takeda S., Earnshaw WC.,Merdes A., Morrison C.: Centrosome amplification induced by DNA damage occurs
during a prolonged G2 phase and involves ATM. EMBO J 2004, 23:3864-3873.
121. Alderton GK., Joenje H., Varon R., Borglum AD., Jeggo PA., O''Driscoll M.: Seckel syndrome exhibits cellular features demonstrating defects in the ATR-signalling
pathway. Hum Mol Genet 2004, 13:3127-3138.
122. Xu X., Weaver Z., Linke SP., Li C., Gotay J., Wang XW., Harris CC., Ried T., Deng CX.:Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic
instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999, 3:389-395.
123. Griffin CS., Simpson PJ., Wilson CR., Thacker J.: Mammalian recombination-repair genes XRCC2 and XRCC3 promote correct chromosome segregation. Nat Cell Biol 2000,
2:757-761.
124. Xie W., Li L., Cohen SN.: Cell cycle-dependent subcellular localization of the TSG101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency. Proc Natl Acad Sci U S A 1998, 95:1595-1600.
125. Freed E., Lacey KR., Huie P., Lyapina SA., Deshaies RJ., Stearns T., Jackson PK.:Components of an SCF ubiquitin ligase localize to the centrosome and regulate the
centrosome duplication cycle. Genes Dev 1999, 13:2242-2257.
126. Dutertre S., Descamps S., Prigent C.: On the role of aurora-A in centrosome function.Oncogene 2002, 21:6175-6183.
127. Oda-Sato E., Tanaka N.: Abnormal Centrosome Amplification and Aurora-A Activation in p53-deficient Cells. Journal of Nippon Medical Scool 2007, 74:384-385.
128. Fichter CD., Herz C., Munch C., Opitz OG., Werner M., Lassmann S.: Occurrence of multipolar mitoses and association with Aurora-A/-B kinases and p53 mutations in
aneuploid esophageal carcinoma cells. BMC Cell Biol 2011, 12:13.
129. Cristina Montagna ERA, Hesed Padilla-Nash, William J Muller and, Thomas Ried:Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2 neu define mouse mammary gland adenocarcinomas induced by mutant HER2 neu. Oncogene 2002, 21:9.
130. Malathy P. V. Shekhar AL, Daniel W. Visscher, Henry Heng, and Noelle Kondrat: Rad6 Overexpression Induces Multinucleation, Centrosome Amplification,. CANCER
RESEARCH 2002, 62:11.
131. Harold I Saavedra, Jeffrey A Knauf, Jill M Shirokawa, Jianwei Wang, Bin Ouyang, Rosella Elisei, Peter J Stambrook, and James A Fagin: The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 2000, 19:7.
132. Paola Fortugno NRW, Alessandra Giodini, Daniel S. O’Connor, Janet Plescia, Karen M. Padgett, Simona Tognin, Pier Carlo Marchisio and Dario C. Altieri: Survivin exists in immunochemically distinct. Journal of Cell Science 2002, 3:11.
133. B.Little J.: Radiation carcinogenesis. Carcinogenesis. Carcinogenesis 2000, 21:8.
134. Aggarwa MHaBB: Differential Roles of Two Types of the TNF Receptor in TNF-Induced Cytotoxicity, DNA Fragmentation, and Differentiation. Journal of Immunology 1994,152:9.
135. P. Chaturvedi WKE, Y. Zhu, M.R. Mattern, R. Mishra, M.R. Hurle, X. Zhang, R.S. Annan, Q.57 Lu, L.F. Faucette, G.F. Scott, X. Li, S.A. Carr, R.K. Johnson, J.D. Winkler, B.B. Zhou,:Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 1999, 18:8.
136. S Masunaga M, K Ono, MD and M Abe, MD: The detection and modification of the hypoxic fraction in quiescent cell populations in murine solid tumours. British Journal
of Radiology 1993, 66:9.
137. Geldof AA., Plaizier MA., Duivenvoorden I., Ringelberg M., Versteegh RT., Newling DW.,Teule GJ.: Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line. J Cancer Res Clin Oncol 2003, 129:175-182.
138. 楊維傑主編: 癌症腫瘤醫論醫話精選 樂群文化事業公司 1989, 176.
139. Louis B. Harrison MC, Richard J. Hill, Kenneth HU,Daniel Shasha: Impact of Tumor Hypoxia and Anemia on Radiation Therapy Outcomes. Oncologist 2002, 7:18.
140. Manfredi JJ., Horwitz SB.: Taxol: an antimitotic agent with a new mechanism of action. Pharmacology & therapeutics 1984, 25:43.
141. Peter B., Schiff and Susan Band Horwitz: Taxol stabilizes microtubules in mouse fibroblase cells. Proceedings of the National Academy of Sciences of the United States of America 1980, 77:5.
142. Liebmann J., Cook JA., Fisher J., Teague D., Mitchell JB.: Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (taxol®).
International Journal of Radiation Oncology Biology Physics 1994, 29:559-564.
143. Dewys WD BC., Lavin PT., Band PR., Bennett JM., Bertino JR., Cohen MH., Douglass HO Jr.,Engstrom PF., Ezdinli EZ., Horton J., Johnson GJ., Moertel CG., Oken MM., Perlia C.,Rosenbaum C., Silverstein MN., Skeel RT., Sponzo RW., Tormey DC.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980, 69:7.
144. Gupta R., Ihmaidat H.: Nutritional effects of oesophageal, gastric and pancreatic carcinoma. Eur J Surg Oncol 2003, 29:10.

電子全文 電子全文(本篇電子全文限研究生所屬學校校內系統及IP範圍內開放)
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top